TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: rhuFVIIa in Post-partum Hemorrhage

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Severe postpartum hemorrhage, i.e non responsive to sulprostone infusion~Exclusion Criteria:~* \< 18 years~* personal antecedent of arterial or venous thrombosis~* written informed consent not approved/signed by the patient or her husband

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Standard care for post-partum hemorrhage (Type: ACTIVE_COMPARATOR): The patients included in this arm of the study will recieve standard care for post-partum hemorrhage.
- rFVIIa (Type: EXPERIMENTAL): The patients included in this arm of the study will recieve standard care for post-partum hemorrhage plus a slow intravenous injection (2ml/min) of rFVIIa (60µg/kg)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Cognitive Behavioral Therapy for Treatment of Adult Attention Deficit Hyperactivity Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of adult ADHD of at least mild clinical severity (CGI score of 3 or greater)~* Stable on medications for adult ADHD for at least 2 months~* Between 18 and 65 years old~* Be able to give informed consent and comply with study procedures~Exclusion Criteria:~* Moderate to severe major depression, clinically significant panic disorder (CGI for depression or panic greater than 4), bipolar disorder, organic mental disorders, psychotic disorders, or pervasive developmental disorders~* Active suicidality (HAM-D suicidality item rated 3 or 4)~* Current substance abuse or dependence~* IQ less than 90~* Suicide risk~* Prior participation in cognitive behavioral therapy for ADHD

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Cognitive-Behavioral Therapy (Type: EXPERIMENTAL): Participants will receive cognitive-behavioral therapy following our protocol.
- Relaxation with Educational Support (Type: ACTIVE_COMPARATOR): Applied relaxation plus educational support (RES).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of SUNPG1623

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Subject has provided written informed consent~* Subject is ≥ 18 years of age at time of Screening~* Subject must be on stable dose of NSAID for ≥ 4 weeks prior to initiation of IMP~* Subject has a negative evaluation for TB within 4 weeks before initiating IMP~* Subject has a diagnosis of PsA (by the Classification of Psoriatic Arthritis \[CASPAR\] criteria) with symptoms present for at least 6 months.~* Subject has ≥ 3 tender and ≥ 3 swollen joints at Screening and Baseline.~Exclusion Criteria:~* Subject has a planned surgical intervention between Baseline and the Week 24 evaluation for a pretreatment condition~* Subject has an active infection or history of infections~* Subject has any concurrent medical condition or uncontrolled, clinically significant systemic disease~* Subject has a known history of infection with hepatitis B, hepatitis C, or human immunodeficiency virus

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SUNPG1623 dose I (Type: EXPERIMENTAL): low range dose
- SUNPG1623 dose II (Type: EXPERIMENTAL): mid range dose
- SUNPG1623 dose III (Type: EXPERIMENTAL): mid range dose
- SUNPG1623 dose IV (Type: EXPERIMENTAL): mid range dose to high dose
- Placebo (Type: PLACEBO_COMPARATOR): mid range dose to high dose

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: RAINBOW Study: RAnibizumab Compared With Laser Therapy for the Treatment of INfants BOrn Prematurely With Retinopathy of Prematurity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* preterm infants with a birth weight of less than 1500 g~* bilateral ROP with one of the following retinal findings in each eye: Zone I, stage 1+, 2+, 3 or 3+ disease, or Zone II, stage 3+ disease, or Aggressive posterior retinopathy of prematurity (AP-ROP)~Exclusion Criteria:~* ROP disease characteristic in either eye other than that listed above at the time of the first investigational treatment~* A history of hypersensitivity (either the patient or the mother) to any of the investigational treatments or to drugs of similar chemical classes~* Had received any previous surgical or nonsurgical treatment for ROP (e.g., ablative laser therapy or cryotherapy, vitrectomy)~* Had been previously exposed to any intravitreal or systemic anti-VEGF agent (either the patient or the mother during this child's pregnancy)~* Had used (either the patient or the mother) other investigational drugs as part of another clinical study (other than vitamins and minerals) within 30 days or within 5 half-lives of the other investigational drug, whichever was longer~* Had ocular structural abnormalities that were assessed by the Investigator to have had a clinically significant impact on study assessments~* Had active ocular infection within 5 days before or on the day of first investigational treatment~* Had a history of hydrocephalus requiring treatment~* Had a history of any other neurological conditions that are assessed by the Investigator to have a significant risk of severe impact on visual function~* Had any other medical conditions or clinically significant comorbidities or personal circumstances that were assessed by the Investigator to have a clinically relevant impact on study participation, any of the study procedures, or on efficacy assessments (e.g., poor life expectancy, pupil not able to be adequately dilated, unable to comply with the visit schedule)

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ranibizumab 0.2 mg (Type: EXPERIMENTAL): 1 intravitreal injection in both eyes on Day 1 (Baseline), with up to 2 re-treatments allowed for each eye if required
- Ranibizumab 0.1 mg (Type: EXPERIMENTAL): 1 intravitreal injection in both eyes on Day 1 (Baseline), with up to 2 re-treatments allowed for each eye if required
- Laser therapy (Type: ACTIVE_COMPARATOR): Laser treatment to each eye on Day 1 (Baseline), with supplementary treatments allowed

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase I/II Clinical Trial for Treatment of Aromatic L-amino Acid Decarboxylase (AADC) Deficiency Using AAV2-hAADC

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. With a confirmed diagnosis of AADC, including cerebrospinal fluid analysis to show reduced levels of neurotransmitter metabolites, HVA and 5-HIAA, and higher L-Dopa, together with more than one mutation within AADC gene.~2. Classical clinical characteristics of AADC deficiency, such as oculogyric crises, hypotonia and developmental retardation.~3. The sick child has to be over 2 years old or a head circumference big enough for surgery.~4. Participating patients must cooperate completely for all evaluations and examinations before, during and after the whole trial.~5. Parents or guardians must sign to agree on this informed consent.~Exclusion criteria~1. Significant brain structure abnormality~2. Patients with any health or neurological doubts that may increase the risk of surgery cannot join this trial. PI has the right to evaluate the feasibility of subjects for this trial based on his/her health condition.~3. Since high-level neutralizing antibodies may disturb the therapeutic effect of gene therapy, patients with anti-AAV2 neutralizing antibody titer over 1,200 folds or an ELISA OD over 1 cannot be enrolled into this trial.~4. Subjects enrolled in this clinical trial cannot take any medications that may affect this trial.

- Gender: ALL
- Minimum Age: 24 Months
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Gene therapy (Type: EXPERIMENTAL): Intracerebral infusion of AAV2-hAADC viral vector will be performed

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Comparison of Antiplatelet Therapies in Asian Subjects With Acute Coronary Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* A person who has been diagnosed with acute coronary syndrome (ACS) and is to undergo a percutaneous coronary intervention (PCI)~* A person who is of East or Southeast Asian descent~* A person who is of the legal age of 18 (or age 21 in Singapore) and is mentally competent to provide a signed written informed consent before entering the study~* If a woman is of childbearing potential, she must test negative for pregnancy and agree to use a reliable method of birth control~Exclusion Criteria:~* A person who has a severe cardiovascular condition such as cardiogenic shock at the time of randomization, ventricular arrhythmias or congestive heart failure~* A person who is at an increased risk of bleeding (e.g. active internal bleeding, history of bleeding disorder, recent fibrinolytic therapy before randomization into the study)~* A person who has prior history of any one of the following: ischemic or hemorrhagic stroke; intracranial neoplasm, arteriovenous malformation, or aneurysm; prior history of transient ischemic attack (TIA)~* A person who needs to take other antiplatelet therapy other than Aspirin for the duration of the study~* A person who receives daily treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) or cyclooxygenase-2 (COX2) inhibitors that cannot be discontinued~* A person who has a severe liver disease, such as cirrhosis~* A person who has a condition such as alcoholism, mental illness, or drug dependence

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Prasugrel 60/10 Primary (Type: EXPERIMENTAL): Loading dose 60 mg followed by maintenance dose 10 mg/day
- Prasugrel 30/7.5 Primary (Type: EXPERIMENTAL): Loading dose 30 mg followed by maintenance dose 7.5 mg/day
- Prasugrel 30/5 Primary (Type: EXPERIMENTAL): Loading dose 30 mg followed by maintenance dose 5 mg/day
- Clopidogrel 300/75 Primary (Type: ACTIVE_COMPARATOR): Loading dose 300 mg followed by maintenance dose 75 mg/day
- Prasugrel 30/5 Low Weight/Elderly (Type: EXPERIMENTAL): Loading dose 30 mg followed by maintenance dose 5 mg/day
- Clopidogrel 300/75 Low Weight/Elderly (Type: ACTIVE_COMPARATOR): Loading dose 300 mg followed by maintenance dose 75 mg/day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Continued Efficacy and Safety of Zoledronic Acid (q 4 Wks vs. q 12 Wks) in the 2nd Year of Treatment in Patients With Bone Metastases From Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~Female patients ≥ 18 years of age. Confirmed breast cancer with bone metastasis. Pretreated with Zometa®, or Aredia (pamidronate) or all sequential regimens of both, for a minimum of 9 doses;~Exclusion Criteria:~Abnormal kidney function determined by serum creatinine levels. Current active dental problems including: ongoing infection of the teeth or jawbone; current exposed bone in the mouth; and current or prior diagnosis of osteonecrosis of the jaw.~Recent (within 8 weeks) or planned dental or jaw surgery (e.g., extraction, implants).~Diagnosis of metabolic bone disease other than osteoporosis (e.g., Paget's disease of bone).~Known hypersensitivity to Zometa. Treatment with other investigational drugs within 30 days prior to randomization.~Other protocol-defined exclusion criteria may have applied.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Zoledronic acid every (q) 4 weeks (Type: EXPERIMENTAL): Participants received 4mg of zoledronic acid intravenously (IV) infusion q 4 weeks.
- Zoledronic acid q 12 weeks (Type: EXPERIMENTAL): Participants received 4 mg zoledronic acid IV q 12 weeks and received placebo to Zometa IV at the 4 week intervals between the q 12 week zoledronic acid infusions in order to maintain the blind.
- Placebo / zoledronic acid (Type: EXPERIMENTAL): Participants randomized to this arm received placebo but the arm was later dropped and participants in this arm were swithced to the zoledronic acid q 4 weeks according to a study amendment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: TR-701 FA vs. Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with systemic signs of infection diagnosed with acute bacterial skin and skin structure infection (ABSSSI)~* Diagnosed with Cellulitis/ erysipelas, major cutaneous abscess, or wound infections~Exclusion Criteria:~* Uncomplicated skin infections~* Severe sepsis or septic shock~* ABSSSI solely due to gram-negative pathogens

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TR-701 FA (Type: EXPERIMENTAL): TR0-701 FA 200 mg tablets once a day for six days followed by 4 days of placebo
- Linezolid (Type: ACTIVE_COMPARATOR): Linezolid 600 mg tablets oral twice a day for 10 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Prevention of Cardiovascular Disease Using a Single PolyPill in an Urban Population - Focus on Liver-Related Variables.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~- Being enrolled in Golestan Cohort Study~Exclusion Criteria:~* Debilitating disease causing inability to comply~* Contraindications to any of the components of PolyPill~* Not consenting to the study

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Polypill (Type: EXPERIMENTAL): Single daily dose of PolyPill and 6-monthly visits
- Control (Type: NO_INTERVENTION): Only 6-monthly visits

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Description of the Use of fidAxomicin in Hospitalized Patients With Documented Clostridium diFficile iNfection and of the managEment of These Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Hospitalized patient~* Patient diagnosed with CDI~Exclusion Criteria:~* Patient already included in this study~* Patient is taking part in a clinical trial in the field of CDI

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1: CDI in patients treated with fidaxomicin (Type: None): Diagnosed with a CDI and treated with fidaxomicin
- 2: CDI in patients receiving treatment other than fidaxomicin (Type: None): Diagnosed with a CDI, regardless of the prescribed treatment (not fidaxomicin)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase II Study of Tipifarnib in Squamous Head and Neck Cancer With HRAS Mutations

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* histologically or cytologically confirmed diagnosis of thyroid cancer (cohort 1) or Squamous Cell Carcinoma head and neck cancer (cohort 2) or Squamous Cell Carcinoma other than HNSCC (cohort 3) for which there is no curative therapy available.~* tumor that carries a missense HRAS mutation ith a variant allele frequency (VAF) \> 20%.~* Subject consents to provide at least 10 unstained tumor slides for retrospective testing of HRAS gene tumor status~* Subject has measurable disease according to RECIST v1.1 and has relapsed or is refractory to prior therapy.~* At least 2 weeks since the last systemic therapy or radiotherapy regimen prior to enrolment~* ECOG PS 0 or 1~* Acceptable liver function~* Acceptable renal function~* Acceptable hematologic status • Serum albumin ≥ 3.5 g/dL. Subjects with tumors potentially highly sensitive to tipifarnib (HRAS mutant VAF ≥ 35%) may be enrolled despite a serum albumin \< 3.5 g/dL.~Exclusion Criteria:~* Prior treatment with an FTase inhibitor~* History of relevant coronary heart disease or myocardial infarction within last 3 years, NYHA Grade III or greater congestive heart failure, cerebro-vascular attack within the prior year, or serious cardiac arrhythmia requiring medication except atrial fibrillation.~* Known uncontrolled brain, leptomeningeal or epidural metastases (unless treated and well controlled for at least 4 weeks prior to Cycle 1 Day 1). Controlled brain metastases that require continuous high dose corticosteroid use within 4 weeks of Day 1.~* Non-tolerable \> Grade 2 neuropathy or evidence of unstable neurological symptoms within 4 weeks first dose~* Major surgery, other than diagnostic surgery, within 4 weeks prior to first dose, without complete recovery.~* Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy. Known infection with HIV, or an active infection with hepatitis B or hepatitis C

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort 1 (Type: EXPERIMENTAL): Thyroid Cancer
- Cohort 2 (Type: EXPERIMENTAL): Squamous Head and Neck Cancer

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Awakening Versus Bedtime Dosing of Ramipril in Subjects With Essential Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Essential hypertension~Exclusion Criteria:~* Severe hypertension.~* Secondary hypertension.~* Grade III/IV hypertensive retinopathy.~* Type 1 diabetes.~* Cerebrovascular or cardiovascular event during the last 12 months prior to inclusion.~* Pregnant or lactating females.~* History of malignancy within the past five years.~* Shift workers.~* Obstructive sleep apnea.~* Use of disallowed concomitant medication.~* Intolerant to ABPM.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Ramipril on awakening
- 2 (Type: ACTIVE_COMPARATOR): Ramipril at bedtime

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete